NCT04910776 - Clinical Study for Treatment-naïve IOPD Babies to Evaluate Efficacy and Safety of ERT With Avalglucosidase Alfa | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 1, 2021

Primary Completion Date

March 6, 2026

Study Completion Date

August 10, 2027

Conditions

Glycogen Storage Disease Type II

Interventions

DRUG

avalglucosidase alfa

Sterile lyophilized powder intravenous (IV) infusion

Trial Locations (16)

Investigational Site Number : 1580001, Taipei

Investigational Site Number : 0560001, Leuven

Advanced Medical Genetics- Site Number : 8400002, Hawthorne

Investigational Site Number : 3800002, Monza

Duke University Medical Center- Site Number : 8400004, Durham

Investigational Site Number : 2760001, Bad Oeynhausen

Cincinnati Children's Hospital Medical Center- Site Number : 8400001, Cincinnati

Children's Hospitals and Clinics of Minnesota- Site Number : 8400008, Minneapolis

Stanford Hospital- Site Number : 8400006, Stanford

Seattle Children's Hospital- Site Number : 8400003, Seattle

Investigational Site Number : 1560001, Shanghai

Investigational Site Number : 1560002, Qingdao

Investigational Site Number : 5280001, Rotterdam

Investigational Site Number : 7240001, Esplugues de Llobregat

Investigational Site Number : 8260001, London

Investigational Site Number : 8260002, Manchester